| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock (or common stock equivalents) at a public offering price of $0.70 per share (or $0.6999 per common stock equivalent).
Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the offering.
In addition, Palisade has granted the underwriters a 45-day option to purchase up to an additional 25,714,285 shares of its common stock at the public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Palisade, are expected to be approximately $120 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about October 2, 2025, subject to the satisfaction of customary closing conditions.
Posted In: PALI
